Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 171-181 , February 2009

In vitro and in vivo analysis of [64Cu-NO2A-8-Aoc-BBN(7–14)NH2]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors

  • Adam F. Prasanphanich

      Affiliations

    • Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • Lauren Retzloff

      Affiliations

    • Department of Molecular Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • ,
  • Stephanie R. Lane

      Affiliations

    • Department of Chemistry, University of Missouri, Columbia, MO 65211, USA
    • ,
  • Prasant K. Nanda

      Affiliations

    • Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • ,
  • Gary L. Sieckman

      Affiliations

    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • Tammy L. Rold

      Affiliations

    • The Radiopharmaceutical Sciences Institute, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • ,
  • Lixin Ma

      Affiliations

    • Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • The Radiopharmaceutical Sciences Institute, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • International Institute of Nano and Molecular Medicine, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • ,
  • Said D. Figueroa

      Affiliations

    • Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • Samantha V. Sublett

      Affiliations

    • The Radiopharmaceutical Sciences Institute, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • ,
  • Timothy J. Hoffman

      Affiliations

    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • The Radiopharmaceutical Sciences Institute, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • ,
  • Charles J. Smith

      Affiliations

    • Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • Department of Molecular Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • The Radiopharmaceutical Sciences Institute, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • University of Missouri Research Reactor Center, University of Missouri, Columbia, MO 65211, USA
    • Corresponding Author InformationCorresponding author. Harry S. Truman Memorial VA Hospital, Research Service Room A005, 800 Hospital Drive, Columbia, MO 65201, USA. Tel.: +1 573 814 6000x53683; fax: +1 573 882 1663.

Received 3 October 2008 ,Revised 4 November 2008 ,Accepted 11 November 2008.

References 

  1. Kung HC, Hoyert DL, Hu J, Murphy SL. Deaths: final data for 2004. Nat Vital Stat Rep. 2008;56(10):
  2. American Cancer Society. Breast cancer facts & figures. Atlanta: American Cancer Society, Inc.; 2007-2008;
  3. American Cancer Society. Cancer facts & figures. Atlanta: American Cancer Society, Inc.; 2008;
  4. Prasad NS, Houserkova D. The roles of various modalities in breast imaging. Biomed Pap Fac Univ Palacky Olomouc Czech Repub. 2007;151:209–218
  5. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353:1773–1783
  6. Kaida H, Ishibashi M, Fujii T, Kurata S, Ogo E, Tanaka M, et al. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device. Ann Nucl Med. 2008;22:95–101
  7. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumors: an update. Breast Can Res Treat. 2004;83:249–289
  8. Engel LW, Young NA. Human breast carcinoma cells in continuous culture: a review. Can Res. 1978;38:4327–4339
  9. Giacchetti S, Gauville C, de Cremoux P, Bertin L, Berthon P, Abita JP, et al. Characterization, in some human breast cancer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Can. 1990;46:293–298
  10. Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC, et al. [64Cu-NOTA-8-Aoc-BBN(7–14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A. 2007;104:12462–12467
  11. Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48:1327–1337
  12. Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2007;101:175–183
  13. Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, et al. Molecular imaging of gastrin-releasing peptide receptor positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-Bombesin(1-14). Bioconj Chem. 2007;18:724–730
  14. Guojun W, Wei G, Kedong O, Yi H, Yanfei X, Qingmei C, et al. A novel vaccine targeting pastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo. Endorc-Rel Can. 2008;15:149–159
  15. Zhou J, Chen J, Mokotoff M, Zhong R, Shultz LD, Ball ED. Bombesin/gastrin-releasing peptide receptor: a potent target for antibody-mediated therapy of small cell lung cancer. Clin Can Res. 2003;9:4953–4960
  16. Ma L, Yu P, Veerendra B, Rold TL, Retzloff L, Prasanphanich AF, et al. In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7–14]NH2 peptide conjugate, a high affinity-fluorescent probe with high selectivity for the gastrin-releasing peptide receptor. Mol Imaging. 2007;6:171–180
  17. Giblin MF, Gali H, Sieckman GL, Owen NK, Hoffman TJ, Volkert WA, et al. In vitro and in vivo evaluation of 111In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers. Breast Can Res Treat. 2006;98:7–15
  18. Aliaga A, Rousseau JA, Ouellette R, Cadorette J, van Lier JE, Lecomte R, et al. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nuc Med Bio. 2004;31:761–770
  19. Sprague JE, Peng Y, Fiamengo AL, Woodin KS, Southwick EA, Weisman GR, et al. Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate Imaging Agents. J Med Chem. 2007;50:2527–2535
  20. Weiner RE, Thakur ML. Radiolabeled peptides in oncology. Biodrugs. 2005;19:145–163
  21. Nijsen JFW, Krijer GC, van het Schip AD. The bright future of radionuclides for cancer therapy. Anti-Can Agents Med Chem. 2007;7:271–290
  22. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Bio. 1996;23:957–980
  23. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Cur Pharmaceutical Des. 2007;13:3–16
  24. Di Bartolo NM, Sargeson AM, Smith SV. New 64Cu PET imaging agents for personalized medicine and drug development using the hexa-aza cage, SarAr. Org Biomol Chem. 2006;4:3350–3357
  25. Gasser G, Tjioe L, Graham B, Belousoff , Juran S, Walther M, et al. Synthesis, copper(II) complexation, 64Cu-labeling, and bioconjugation of a new bis(2-pyridylmethyl) derivative of 1,4,7-triazacyclononane. Bioconj Chem. 2008;19:719–730
  26. Kukis DL, Li M, Meares CF. Selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals. Inorg Chem. 1993;32:3981–3982
  27. Voss SD, Smith SV, Di Bartolo NM, McIntosh LJ, Cyr EM, Bonab AA, et al. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A. 2007;104:17489–17493
  28. Di Bartolo NM, Sargeson AM, Donlevy TM, Smith SV. Synthesis of a new cage ligand, SarAr, and its complexation with selected transition metal ions for potential use in radioimaging. J Chem Soc Dalton Trans. 2001;2303–2309
  29. Pippin CG, Kumar K, Mirzadeh S, Gansow OA. Kinetics of the isotopic exchange between copper(II) and copper(II) 1,4,7-triazacyclononane-N,N′,N′ triacetate. J Label Compd Radiopharm. 1991;30:221
  30. Geraldes CFGC, Marques MP, de Castro B, Pereira E. Study of copper(II) polyazamacrocyclic complexes by electronic absorption spectrophotometry and EPR spectroscopy. Eur J Inorg Chem. 2000;559–565
  31. Wieghardt K, Bossek U, Chaudhuri P, Herrmann W, Menke BC, Weiss J. 1,4,7-Triazacyclononane-N,N′,N″-triacetate (TCTA), a hexadentate ligand for divalent and trivalent metal ions. Crystal structures of [CrIII(TCTA)], [FeIII(TCTA)], and Na[CuII(TCTA)]•2NaBr•8H2O. Inorg Chem. 1982;21:4308–4314
  32. van der Merwe MJ, Boeyens JCA, Hancock RD. Crystallographic and thermodynamic study of metal ion size selectivity in the ligand 1,4,7-triazacyclononane-N,N′,N″-triacetate. Inorg Chem. 1985;24:1208–1213
  33. Prasanphanich AF, Lane SR, Figueria SD, Ma L, Rold TL, Sieckman GL, et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals. In Vivo. 2007;21:1–16
  34. Soluri A, Scopinaro F, de Vincentis G, Varvarigou A, Scafe R, Massa R, et al. 99mTc [13Leu] bombesin and a new gamma camera, the probe, are able to guide mammotome breast biopsy. Antican Res. 2003;23:2139–2142
  35. Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi JC, et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med. 2005;46:823–830
  36. Monstein HJ, Grahn N, Truedsson M, Ohlsson B. Progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA expression in non-tumor tissues of the human gastrointestinal tract. World J Gastroenterol. 2006;12:2574–2578
  37. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature. 2007;488:700–703
  38. Roesler R, Lessa D, Venturella R, Vianna MRM, Luft T, Henriques JAP, et al. Bombesin/gastrin-releasing peptide receptors in the basolateral amygdale regulate memory consolidation. Eur J Neurosci. 2004;19:1041–1045
  39. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465–1474
  40. Gotthardt M, van Eerd-Vismale J, Oyen WJG, de Jong M, Zhang H, Rolleman E, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med. 2007;48:596–601
  41. Rubin P, Casarett GW. Clinical radiation pathology as applied to curvature radiotherapy. Cancer. 2006;22:767–778

☆ This work was funded in part by The United States Department of Veterans' Affairs VA Merit Award.

PII: S0969-8051(08)00245-X

doi: 10.1016/j.nucmedbio.2008.11.005

Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 171-181 , February 2009

Article Tools

* Image Usage & Resolution